NCT Number: NCT00156143
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.
Looking for future studies?
Notify MeKey information
Conditions
Age range
15 year–20 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Males or females : Chronological age > or = 15 years and < or = 20 years for females
- Chronological age > or = 17 years and < or = 20 years for males
- GHD of childhood onset treated for at least 2 years
- Last GH injection at least 12 months before baseline visit
Exclusion criteria
- Turner's syndrome
- Chronic hepatic impairment as shown by GGT and / or ASAT and / or ALAT > 2 X ULN
Treatment and study plan
Radiography
ProcedurePrimary outcomes
-
Change from baseline of the % of fat mass assessed by DEXA after 1 year of treatment.
Sponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Official study title
GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.
Acronym: TAUBER
Important dates
- Study start
- 2002
- Study completion
- 2005
- First posted
- Sep 12, 2005
- Registry last updated
- Jul 30, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
NCT04615273
Bone Diseases, Bone Diseases, Developmental
Birmingham, Alabama, United States
View Trial DetailsPhase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
NCT04614337
Bone Diseases, Bone Diseases, Developmental
Sacramento, California, United States
View Trial DetailsPhase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
NCT05250063
Bone Diseases, Bone Diseases, Developmental
San Diego, California, United States
View Trial DetailsGrowth and Asymmetric diMethylArginine
NCT03422081
Bone Diseases, Bone Diseases, Developmental
Lille, France
View Trial Details